Shuwen Biotech Secures Nearly RMB 100 Million in Series B Funding to Accelerate Innovation in Diagnostic Solutions

VCBeat has learned that Zhejiang Shuwen Biotech Co., Ltd. (hereinafter referred to as “Shuwen Biotech”) recently announced the completion of its Series B financing, amounting to nearly RMB 100 million. The round was led by Guolian Investment, with participation from Shuncheng Capital, Anyuan Fund, and Kaichuang Fund. Previously, Shuwen Biotech received continued investment from Yuesheng Venture Capital, and its Series A+ round attracted capital injections from multiple specialized healthcare investment institutions, including Boyi Fund.

Upon the completion of this round of financing, Zhejiang Shuwen Biotech Co., Ltd. will make significant strides in securing external funding and enhancing its operational capabilities, thereby providing robust support for its sustained commitment to the development, production, and marketing of innovative products in the fields of cancer screening, maternal and child health, and reproductive health.

Regarding the successful completion of this round of financing, Dr. Zhang Yizhe, Founder and General Manager of Shuwen Biotech, stated: “For many years, our team at Shuwen has been dedicated to the development of first-in-class, globally novel in vitro diagnostic reagents—a endeavor akin to sharpening a sword for ten years. We have resolutely persisted on the path of innovation to this day. At this moment, I am deeply grateful to our fund shareholders who have consistently placed great trust in and provided steadfast support to Shuwen Biotech, as well as to the new investment institutions joining this financing round. It is their discerning vision and enthusiasm for innovation that have empowered our team to remain committed to this challenging journey of entrepreneurship and innovation. Leveraging the momentum from this financing round, we will continue to invest in the development of innovative products, while simultaneously initiating or accelerating the domestic and international market promotion of our mature, commercially launched products and services. In China, as we vigorously promote our precision medicine products and services for breast cancer, we will continue to collaborate with our partner, PerkinElmer, to rapidly expand the adoption of Wenxian’an.”^®"The clinical application of rapid urine tests for preeclampsia in pregnant women provides a novel approach to addressing clinical challenges. In Europe and other international markets, we will promote our own first-in-class molecular diagnostics for breast cancer and rapid tests for preeclampsia in pregnant women through Shuwen’s wholly-owned subsidiary in Germany, thereby establishing our own distribution channels and brand."

Regarding new product development, Dr. Li Xingmin, General Manager of the R&D Center at Zhejiang Shuwen Biotech Co., Ltd., stated: “On one hand, the company will provide one-stop solutions across various stages in the oncology field, particularly for early screening, precision medicine, companion diagnostics, prognosis, and recurrence monitoring of breast cancer; on the other hand, it will focus on ‘Wen Xian An’^®- The preeclampsia detection kit” as a representative, we continue to strengthen our efforts in the field of maternal and child reproductive health, consistently providing the market with innovative products that are high-quality, affordable, and address unmet clinical needs.”

Dr. Xue Zhifeng, Head of Medical and Healthcare Investments at Wuxi Guolian Investment, the lead investor in this round, stated: “Shuwen Biotech is one of the few innovative companies in China’s in vitro diagnostics sector that effectively integrates independent R&D with the introduction of international collaborative technologies. Its launched product, Wenxian’an,”^®TAPE with Mom^®Both IVD products are global first-in-class innovations with strong patent and technological barriers, and have been independently validated by multiple institutions through international clinical studies. Among them, Wenxian'an^®“To the best of our knowledge, this is the first domestically developed, globally pioneering product to be successfully licensed to a multinational corporation. Zhejiang Shuwen Biotech has laid out two innovative products and is promoting them in international markets based on innovation and clinical value, which stands in stark contrast to many domestic peers that compete internationally with low-priced, homogeneous products. We believe that the company will undoubtedly become an internationally leading, globalized innovative diagnostics enterprise within three to five years. We consider Zhejiang Shuwen Biotech a rare investment opportunity in China’s in vitro diagnostics sector, and we are very pleased that Guolian Investment had the privilege of participating in this round of financing.”

Zhejiang Shuwen Biotech Co., Ltd. is an international company specializing in the development, manufacturing, and sales of in vitro diagnostic (IVD) reagents, as well as medical laboratory services. Headquartered in Deqing, Zhejiang Province, the company has established R&D, production, and sales bases and teams in Hangzhou, Xuancheng (Anhui Province), and Frankfurt, Germany. Recognized as a National High-Tech Enterprise, it hosts the “Provincial Enterprise R&D Center for Innovative Medical Diagnostics” and possesses comprehensive facilities for the production and quality control of diagnostic kits. Furthermore, it is the only provincial-level “International Cooperation Base for Innovative Biomarker Medical Diagnostic Technology” in Zhejiang Province.

Since 2011, Shuwen Biotech has entered into exclusive cooperation agreements with numerous internationally renowned universities, enterprises, and research institutions, including Yale University, the University of Chicago, the Max Planck Institute in Germany, the University of Cologne in Germany, BioNTech, and Myriad Genetics. Leveraging these partnerships alongside independent innovation, the company has secured over 100 exclusive diagnostic patents and successfully developed multiple first-in-class diagnostic products and services. It has established a comprehensive portfolio of products and services in women’s health, particularly in the fields of maternal and child medicine and precision oncology for breast cancer.

Shuwen Guanzhi Medical Laboratory, a subsidiary of Zhejiang Shuwen Biotech Co., Ltd., is a third-party independent laboratory accredited by the College of American Pathologists (CAP). It provides high-quality medical testing services, along with companion diagnostic reagent development and clinical trial sample testing, offering one-stop companion diagnostic solutions to many leading new drug R&D companies. Shuwen Biotech is committed to continuously innovating and launching proprietary diagnostic products, unlocking new possibilities for human health.